Results 1 to 10 of about 21,951 (195)

Acute Promyelocytic Leukemia [PDF]

Cancers, 2020
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) cytogenetically characterized by a balanced reciprocal translocation between chromosomes 15 and 17, which results in the fusion between the promyelocytic leukemia (PML) gene and retinoic acid receptor-α (RARα) [...]
Xavier Thomas, Maël Heiblig
  +6 more sources

History of Acute Promyelocytic Leukemia [PDF]

Clinical Hematology International, 2021
In this article, we discuss the history of acute promyelocytic leukemia (APL) from the pre-therapeutic era, which began after its recognition by Hillestad in 1947 as a nosological entity, to the present day. It is a paradigmatic history that has transformed the "most malignant leukemia form" into the most curable one.
Miguel A. Sanz, Eva Barragán
openaire   +3 more sources

Acute Promyelocytic Leukemia Presenting With a Myeloid Sarcoma of the Spine: A Case Report and Literature Review

Frontiers in Oncology, 2022
Myeloid sarcoma is a rare extramedullary tumor of immature myeloid cells. Certain known acute myeloid leukemia cytogenetic abnormalities, in particular t(8,21), has been associated with a higher incidence.
Xuemei Shu, Qiuling Wu, Tao Guo, Hua Yin, Jingdi Liu   +4 more
doaj   +1 more source

Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia. [PDF]

PLoS ONE, 2016
AIM:All-trans retinoic acid combined to anthracycline-based chemotherapy is the standard regimen of acute promyelocytic leukemia. The advent of arsenic trioxide has contributed to improve the anti-leukemic efficacy in acute promyelocytic leukemia.
Ye Zhang, SiJing Wu, Dan Luo, JianFeng Zhou, DengJu Li   +4 more
doaj   +1 more source

Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism

Haematologica, 2020
Obesity correlates with hematologic malignancies including leukemias, but risk of specific leukemia subtypes like acute promyelocytic leukemia and underlying molecular mechanisms are poorly understood.
Luca Mazzarella, Edoardo Botteri, Anthony Matthews, Elena Gatti, Davide Di Salvatore, Vincenzo Bagnardi, Massimo Breccia, Pau Montesinos, Teresa Bernal, Cristina Gil, Timothy J Ley, Miguel Sanz, Krishnan Bhaskaran, Francesco Lo Coco, Pier Giuseppe Pelicci   +14 more
doaj   +1 more source

Treatment of Central Nervous System Relapse in Acute Promyelocytic Leukemia by Venetoclax: A Case Report

Frontiers in Oncology, 2021
Extramedullary relapse of acute promyelocytic leukemia is a rare phenomenon and is associated with a poor prognosis, with the central nervous system being the most common site of relapse. The current treatments are still limited.
Xuzhao Zhang, Jinliang Chen, Weiqin Wang, Xian Li, Yanbin Tan, Xiaohong Zhang, Wenbin Qian   +6 more
doaj   +1 more source

SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA DEVELOPED AFTER TREATMENT OF NON-HODGKIN'S LYMPHOMA. CLINICAL CASE AND REVIEW OF LITERATURE.

Arta Medica, 2020
Background: Acute promyelocytic leukemia is an acute myeloid leukemia that accounts approximately 10% of acute myeloid leukemia cases. Acute promyelocytic leukemias usually appears as a de novo finding.
Victor Tomacinschii, Maria Robu, Vasile Musteață, Irina Mocanu, Sanda Buruiană, Natalia Sporîș, Veronica Feghiu   +6 more
doaj   +1 more source

The CEBPA gene is down-regulated in acute promyelocytic leukemia and its upstream promoter, but not the core promoter, is highly methylated

Haematologica, 2011
Impairment of CCAAT Enhancer Binding Protein alpha (CEBPA) function is a common finding in acute myeloid leukemia; nevertheless, its relevance for acute promyelocytic leukemia pathogenesis is unclear.
Bárbara Amélia Santana-Lemos, Ana Paula Alencar de Lima Lange, Mariana Tereza de Lira Benício, Thiago Donizete da Silva José, Antônio Roberto Lucena-Araújo, Alexandre Krause, Carolina Hassibe Thomé, Eduardo Magalhães Rego   +7 more
doaj   +1 more source

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group

Haematologica, 2018
In standard-risk acute promyelocytic leukemia, recent results have shown that all-trans retinoic acid plus arsenic trioxide combinations are at least as effective as classical all-trans retinoic acid plus anthracycline-based chemotherapy while being less
Lionel Adès, Xavier Thomas, Agnes Guerci Bresler, Emmanuel Raffoux, Olivier Spertini, Norbert Vey, Tony Marchand, Christian Récher, Arnaud Pigneux, Stephane Girault, Eric Deconinck, Claude Gardin, Olivier Tournilhac, Jean Francois Lambert, Patrice Chevallier, Stephane de Botton, Julie Lejeune, Hervé Dombret, Sylvie Chevret, Pierre Fenaux   +19 more
doaj   +1 more source

Acute Myeloid Leukemia and Acute Promyelocytic Leukemia

Hematology, 2003
AbstractThe therapeutic approach to the patient with acute myeloid leukemia (AML) currently evolves toward new frontiers. This is particularly apparent from the entree of high-throughput diagnostic technologies and the identification of prognostic and therapeutic targets, the introduction of therapies in genetically defined subgroups of AML, as well as
Bob, Löwenberg, James D, Griffin, Martin S, Tallman   +2 more
openaire   +2 more sources